Therapeutic vaccines offer low-toxicity treatment options for early stage disease and may enhance the efficacy of existing regimens in late-stage disease while adding minimal toxicity. Immunotherapy using therapeutic cancer vaccines has the potential to address several unmet medical needs.
Vaccibody focus on internal development of therapeutic vaccines against cancer and is currently running a phase I/IIa study in patients with precancerous cervical lesions.
Vaccibody has in addition compelling preclinical data for Melanoma, Prostate Cancer, B Cell Lymphoma and Multiple Myeloma all showing the platform’s ability to induce strong and long-lasting T cell responses and to effectively eliminate cancer cells. Novel Vaccibody cancer vaccines are currently under development.